Duchenne Muscular Dystrophy

An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy.- Clinical Manifestations and Overall Management Strategies for Duchenne Muscular Dystrophy.- Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies.- Characterization of the Inflammatory Response in Dystrophic Muscle Using Flow Cytometry.- Imaging Analysis of the Neuromuscular Junction in Dystrophic Muscle.- System Biology Approach: Gene Network Analysis for Muscular Dystrophy.- Proteomic Profiling of the Dystrophin-Deficient Brain.- Probing the Pathogenesis of Duchenne Muscular Dystrophy Using Mouse Models.- Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.- Designing Effective Antisense Oligonucleotides for Exon Skipping.- Identification of Splicing Factors Involved in DMD Exon Skipping Events Using an In Vitro RNA Binding Assay.- The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.- PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment.- Proton Nuclear Magnetic Resonance (1H NMR) Spectroscopy-Based Analysis of Lipid Components in Serum / Plasma of Patients with Duchenne Muscular Dystrophy (DMD).- Test of Anti-Fibrotic Drugs in a Cellular Model of Fibrosis Based on Muscle-Derived Fibroblasts from Duchenne Muscular Dystrophy Patients.- Flow Cytometry-Defined CD49d Expression in Circulating T-Lymphocytes is a Biomarker for Disease Progression in Duchenne Muscular Dystrophy.- Advanced Methods to Study the Cross-Talk Between Fibro-Adipogenic Progenitors and Muscle Stem Cells.- AAV6 Vector Production and Purification for Muscle Gene Therapy.- From gRNA Identification to the Restoration of Dystrophin Expression: A Dystrophin Gene Correction Strategy for Duchenne Muscular Dystrophy Mutations Using the CRISPR-Induced Deletion Method.